LIVMARLI is the first and only treatment available for cholestatic pruritus in patients with Alagille syndrome and ...

- LIVMARLI is the first and only treatment available for cholestatic pruritus in patients with Alagille syndrome and Progressive Familial Intrahepatic Cholestasis in Japan Mirum Pharmaceuticals ...

Mirum Pharmaceuticals (MIRM) announced that its partner, Takeda (TAK), has received approval by the Japanese Ministry of Health, Labour, and ...

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) focuses on developing therapies for rare liver diseases caused by bile acid buildup, including progressive familial intrahepatic cholestasis (PFIC) and ...

FOSTER CITY, Calif. - Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a $2.27 billion market cap biotech company with impressive 81% revenue growth over the last twelve months, has announced that its ...

Drug-induced liver injury (DILI) is a significant concern in clinical practice, arising from medications, herbs, and dietary ...

Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Get Free Report) have earned a consensus rating of “Buy” from the eleven research firms that are presently covering the firm, MarketBeat ...

Swiss National Bank boosted its holdings in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Free Report) by 1.9% during the fourth quarter, according to the company in its most recent ...

In this article, we will be taking a look at the 11 best gene therapy stocks to buy according to analysts. Gene therapy is a medical approach that entails changing or modifying genes to treat or ...

GSK has reported promising results with a drug to treat the severe itching that plagues patients with rare cholestatic liver disease primary biliary cholangitis (PBC). Interim results from the ...

- LIVMARLI is the first and only treatment available for cholestatic pruritus in patients with Alagille syndrome and Progressive Familial Intrahepatic Cholestasis in Japan FOSTER CITY, ...